Panion presented at InvestorDagen in Århus, Denmark, the 12.th of June 2018

The progress and plans for Panion's development of the gene therapy treatment for dogs with epilepsy, and for Panion's business idea and vision, was presented by Anja Holm, CEO of Panion, at the InvestorDagen event in Århus, Denmark on the 12.th of June.

A webcast of the presentation can be found here (in Danish): https://getvisualtv.net/stream/?daf-investordagen-aarhus-120618#panion-animal-health

"The day was well-attended with approximately 500 visitors for the entire event, and I experienced good interest for Panion's unique product development and for the presentation. Most people own dogs or cats and can easily understand the willingness to pay for treatments when the pets are seriously ill", says Anja Holm. "It was very satisfying to talk with both existing shareholders and new, interested persons during the day. AktieTorget will enter the Danish market later this year, so we find it very relevant to reach out to interested investors in Denmark."

InvestorDagen, Dansk Aktionærforening, @Shareholders.dk

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.

Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

Panion in FDA pre-submission conference

Panion Animal Health AB develops a unique new gene therapy treatment for dogs with drug-resistant epilepsy and the primary targeted market is the USA. The company has just been assigned to a pre-submission conference for this product with staff and experts from the FDA's Center for Veterinary Medicine to take place in October in FDA-CVM's office, Maryland, USA. At the meeting, the product will be introduced, the development plan will be discussed, and comments from the experts will be sought for a faster and smoother access to approval and marketing.


Panion's emission is finalised and the dog safety study is progressing well

Panion's shares emission that was running from 16-30 May and raised appr. 5.2 MSEK before emission costs, has now been completed and all payments processed.





Nyemission registrerad hos Bolagsverket

Panion Animal Health AB:s (publ) nyemission är nu delregistrerad hos Bolagsverket


Panion's dog safety study experience a slight delay

Panion Animal Health AB develops a unique gene therapy treatment for dogs with idiopathic epilepsy. A safety study in dogs is currently running at the University of Copenhagen under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. Preliminary results from the study were expected in Q2, but due to circumstances outside Panion's influence, Panion has just been informed that this timing has been slightly delayed into Q3.


Panion presented at InvestorDagen in Århus, Denmark, the 12.th of June 2018

The progress and plans for Panion's development of the gene therapy treatment for dogs with epilepsy, and for Panion's business idea and vision, was presented by Anja Holm, CEO of Panion, at the InvestorDagen event in Århus, Denmark on the 12.th of June.


Panion in ITF-meeting at EMA


Panion presents for investors at InvestorDagen in Aarhus, DK on the 12.th of June 2018

Panion Animal Health AB is a Swedish registered company with shares on Spotlight/AktieTorget and with a unique product in development - a gene therapy treatment for epilepsy in dogs. We have  a strong Scandinavian cooperation in that half of Panion's management and board resides in Denmark. A safety study in dogs is currently running in Denmark in cooperation with the University of Copenhagen and under the lead of Associate professor David Woldbye, Department of neuroscience, KU.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: